57341-09-0

Basic information

• Product Name: Benzene, 2-azido-1,3-dichloro-
• Synonyms: Benzene, 2-azido-1,3-dichloro-
• CAS NO: 57341-09-0
• Molecular Formula: C₆H₃Cl₂N₃
• Molecular Weight: 188.01412
• Mol File: 57341-09-0.mol
• Article Data: 21

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzene, 2-azido-1,3-dichloro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 2-azido-1,3-dichloro-(57341-09-0)
• EPA Substance Registry System: Benzene, 2-azido-1,3-dichloro-(57341-09-0)

Safety Data

• Hazardous Substances Data: 57341-09-0(Hazardous Substances Data)

Upstream product

• 608-31-1 2,6-Dichloroaniline 
• 50709-36-9 (2,6-dichlorophenyl)hydrazine monohydrochloride 

Downstream Products

• 959800-65-8 3-(2,6-dichloro-phenyl)-5-isopropyl-3H-[1,2,3]triazole-4-carboxylic acid ethyl ester 
• 959800-90-9 3-(2,6-dichloro-phenyl)-5-trifluoromethyl-3H-[1,2,3]triazole-4-carboxylic acid ethyl ester 
• 959801-10-6 6-(4-[3-(2,6-dichloro-phenyl)-5-trifluoromethyl-3H-[1,2,3]triazol-4-ylmethoxy]-2-methyl-phenyl)-1-isopropyl-1H-indazole-3-carboxylic acid methyl ester 

Relevant articles and documents

MULTICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS

The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of famesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, A, X1